Start the conversation
Comment on This Story
Or to contact Money Morning Customer Service, click here.
It's been touch and go for the stock market, I admit, but the global advancement of cannabis took some significant steps forward over the past few weeks.
This likely points to bigger gains for weed stocks, like the ones in my Nova-X Report Roadmap to Marijuana Millions model portfolio, just around the corner.
The momentum is unstoppable.
Earlier this week, I told my paid-up Nova-X Report readers that popular sentiment has moved much too far in favor of legalization of marijuana for anything - even Jeff Sessions - to stop it.
A Gallup poll last year showed 64% of Americans are in favor of marijuana legalization; more states are setting up legalization campaigns.
And none of this even takes into account the multibillion-dollar potential to be unlocked when the entire nation of Canada legalizes cannabis this summer, as we expect it will.
And just when it seems like things couldn't get much better... they do.
Because now we hear that legal weed will be bigger than wine.
Just take that in for a moment - because it looms large among a couple of pot-bullish developments I want to tell you about this week...
About the Author
Michael A. Robinson is a 36-year Silicon Valley veteran and one of the top tech and biotech financial analysts working today. That's because, as a consultant, senior adviser, and board member for Silicon Valley venture capital firms, Michael enjoys privileged access to pioneering CEOs, scientists, and high-profile players. And he brings this entire world of Silicon Valley "insiders" right to you...
- He was one of five people involved in early meetings for the $160 billion "cloud" computing phenomenon.
- He was there as Lee Iacocca and Roger Smith, the CEOs of Chrysler and GM, led the robotics revolution that saved the U.S. automotive industry.
- As cyber-security was becoming a focus of national security, Michael was with Dave DeWalt, the CEO of McAfee, right before Intel acquired his company for $7.8 billion.
This all means the entire world is constantly seeking Michael's insight.
In addition to being a regular guest and panelist on CNBC and Fox Business, he is also a Pulitzer Prize-nominated writer and reporter. His first book Overdrawn: The Bailout of American Savings warned people about the coming financial collapse - years before the word "bailout" became a household word.
Silicon Valley defense publications vie for his analysis. He's worked for Defense Media Network and Signal Magazine, as well as The New York Times, American Enterprise, and The Wall Street Journal.
And even with decades of experience, Michael believes there has never been a moment in time quite like this.
Right now, medical breakthroughs that once took years to develop are moving at a record speed. And that means we are going to see highly lucrative biotech investment opportunities come in fast and furious.
To help you navigate the historic opportunity in biotech, Michael launched the Bio-Tech Profit Alliance.
His other publications include: Strategic Tech Investor, The Nova-X Report, Bio-Technology Profit Alliance and Nexus-9 Network.
Looking forward to your ideas
You are a GEM Michael! Your portfolio is proof & I've not seen any with the gains you make on you Gem picks. Keep it up & God Bless you indeed!
It is time to challenge the unconstitutional Federal Marijuana laws.